About the Breckenridge Pharm Future Settlement
Breckenridge Pharmaceutical has agreed to reimburse patient prescriptions following discoveries of nitrosamine contamination in their duloxetine products sold between 2020 and 2025. The settlement also establishes a Future Refund program remaining in effect until January 1, 2028.
The settlement ends allegations that Breckenridge distributed cancer-causing impurities in over half a million bottles of generic duloxetine, which the FDA recalled earlier this year.
Why did Breckenridge Consumers Sue?
Class plaintiffs allege that the pharmaceutical defendant manufactured and distributed generic Cymbalta containing dangerous levels of N-nitroso-duloxetine (NDLX) contamination.
According to the lawsuit, laboratory testing revealed that specific batches of duloxetine exceeded the FDA's acceptable daily intake limits for NDLX impurities, prompting immediate action from federal regulators.
What is generic Duloxetine?
Duloxetine serves as a lifeline for millions of Americans managing depression, anxiety disorders, fibromyalgia, and diabetic neuropathy pain. Generic versions, such as those manufactured by Breckenridge, provide affordable treatment options for patients who might otherwise struggle to afford the brand-name Cymbalta.
Government testing and recall
The FDA issued a Class II recall in May 2025 for the affected products, indicating that the use of the medication could cause temporary or medically reversible adverse health effects.
Testing also showed NDLX levels in some batches exceeded acceptable limits by significant margins and contaminated more than 570,000 bottles of duloxetine distributed nationwide in 2025.
Class action attorneys for the plaintiffs have emphasized that when Breckinridge Pharm failed to detect or prevent contamination, consumers bore both the financial burden and potential health risks, breaching both consumer trust and federal law.
Nitrosamines and NDLX Contamination
Nitrosamines represent a class of chemical compounds that form when certain ingredients interact during the manufacturing or storage process.
In pharmaceutical manufacturing, nitrosamines may develop through several pathways including:
- Chemical reactions during synthesis processes.
- Contamination from equipment or raw materials.
- Degradation of active ingredients over time.
- Interaction with packaging materials.
The FDA establishes acceptable NDLX daily intake limits based on lifetime exposure that keep potential cancer risk below one additional case per 100,000 people taking the medication daily for 70 years.
According to the lawsuit, Breckenridge's duloxetine NDLX levels exceeded the FDA’s carefully calculated limits by 220%, triggering recalls and regulatory action.
Future Refund Program Explained
Breckenridge has established a Future Refund Program that operates independently from the class action settlement.
This program addresses potential recalls that might occur after the settlement period ends, providing continued protection for consumers who purchase Breckenridge duloxetine in the future.
The Future Refund Program offers eligible patients the possibility of a full out-of-pocket refund for unused medication, subject to any recall initiated after May 22, 2025.
Future refund program timeline
The Future Refund Program runs from May 22, 2025, to January 1, 2028, and reactivates five days after Breckenridge initiates a product recall during the class period.
This built-in delay allows time for recall notifications to reach consumers and for the claims infrastructure to prepare for submissions.
Breckenridge commits to maintaining the Future Refund Program through at least January 1, 2028, providing nearly three years of additional consumer protection.
Who Qualifies for the Drug Recall Settlement?
Class members who purchased the following recalled Breckenridge duloxetine products after May 22, 2025, may possibly participate in this lawsuit:
- Duloxetine Delayed-Release Capsules USP, 40 mg – Lot: 230199 | Recall Date: June 30, 2025 | NDC: 51991-750-33 | Exp: 01/2026.
- Duloxetine Delayed-Release Capsules USP, 60 mg – Lot: 230836C | Recall Date: July 15, 2025 | NDC: 51991-748-10 | Exp: 02/2026.
- Duloxetine Delayed-Release Capsules USP, 60 mg – Lot: 240539C | Recall Date: July 25, 2025 | NDC: 82009-032-10 | Exp: 01/2027.
- Duloxetine Delayed-Release Capsules USP, 30 mg – Lot: 240927C | Recall Date: Aug. 8, 2025 | NDC: 82009-030-10 | Exp: 04/2027.
- Duloxetine Delayed-Release Capsules USP, 60 mg – Lot: 230286C | Recall Date: Oct. 9, 2025 | NDC: 51991-748-10 | Exp: 02/2026.
- Duloxetine Delayed-Release Capsules USP, 60 mg – Lot: 240721C | Recall Date: Oct. 9, 2025 | NDC: 51991-748-90 | Exp: 02/2027.
Future refund eligibility requirements
To possibly qualify for Future Refund Program benefits, consumers must:
- Return unused recalled medication to designated collection points.
- Provide proof of purchase showing out-of-pocket expenses
- Submit claims within specified timeframes after recall announcements.
- Meet all program requirements as outlined on the official website.
Participating in the Future Refund Program doesn't affect possible participation in the ongoing Beckenridge Pharm class action lawsuit.
How to File a Breckenridge Pharmaceutical Claim
Online Claim
- Visit www.breckenridgefuturerefundprogram.com.
- Choose between creating an account or proceeding as a guest.
- Upload required documentation in PDF or image format.
- Review all information for accuracy.
- Submit your claim and receive a confirmation number.
Mail-In Claim
- Visit www.breckenridgefuturerefundprogram.com.
- Select “I would like to print out and mail a claim form for the Future Refund Program.”
- Complete all required sections.
- Download and print the PDF claim form.
- Make digital copies of supporting documentation.
- Keep originals for your records.
- Mail the completed package to the administrator at: Boyer v. Breckenridge Pharmaceuticals Claims Administrator, P.O. Box 301132, Los Angeles, CA, 90030-1132.
Mail submissions must be postmarked before January 1, 2028. Consider certified mail or delivery confirmation for proof of timely submission.
Important Settlement Dates
January 1, 2028 is the final deadline to submit claims under the future class action settlement. Missing this deadline likely forfeits your right to participation.
The settlement administrator typically posts important updates and deadline reminders on the official website. Consider signing up for email notifications to receive alerts about approaching deadlines or any changes to the settlement timeline.
Learn More About Eligibility
The settlement administrator can assist consumers in obtaining the necessary information to complete future claims. Check eligibility or learn more about the class action lawsuit or future refunds at: www.breckenridgefuturerefundprogram.com.
Add Comment